中国实用妇科与产科杂志2017，Vol.33Issue(3)：288-292,5.DOI:10.19538/j.fk2017030113
血管生成抑制剂联合化疗治疗复发性卵巢癌疗效与安全性Meta分析
Meta-analysis of efficacy and safety of congiogenesis inhibitors combined with chemotherapy in the treatment of patients with recurrent ovarian cancer
李若玢 1欧阳媛 1平文萍 1张琪 1王晓玉1
作者信息
- 1. 暨南大学附属第一医院,广东广州510630
- 折叠
摘要
Abstract
Objective To study the efficacy and safety of angiogenesis inhibitors combined with chemotherapy in treatment of recurrent ovarian cancer.Methods The PubMed,Embase,The Cochrane Library,CBM,CNKI,VIP and Wan Fang Databases were electronically searched for publications from inception to January 2016 to collect randomized controlled trials (RCTs) about the efficacy and safety of angiogenesis inhibitors combined with chemotherapy in the treatment of patients with recurrent ovarian cancer and compared with routine chemotherapy.Literature data screening and bias risk assessing were independently executed by two reviewers.Meta-analysis was performed by Rev Man 5.3 software.Results Overall,6 RCTs involving 2028 recurrent ovarian cancer patients were included.The results were as follows:(1) OS and PFS for the angiogenesis inhibitors group was superior to the control group,respectively [HR=0.87,95％CI (0.76,0.99),P ＜ 0.05] and [HR=0.56,95 ％ CI (0.47,0.67),P ＜ 0.05].(2) There was no significant difference between two group in the total grade 3 or higher (P ＞ 0.05).Grade 3 or higher hypertension and proteinuria occurred more frequently in the anti-VEGF group(P ＜ 0.05).Grade 3 or higher proteinuria and grade 2 or lower diarrhea and nausea occurred more frequently in the anti-VEGFR group(P ＜ 0.05).More incidences of generalized edema occurred in the antiANG group (P ＜ 0.05).Conclusion Angiogenesis inhibitors combined with chemotherapy can improve OS and PFS.The total incidence of adverse reactions is similar to that of the routine chemotherapy group.The type and severity of adverse reactions are different in different mechanisms of angiogenesis inhibitors.关键词
血管生成抑制剂/复发性卵巢癌/系统评价/Meta分析/随机对照试验Key words
angiogenesis inhibitor/recurrent ovarian cancer/systematic review/Meta-analysis/randomized controlled trials分类
医药卫生引用本文复制引用
李若玢,欧阳媛,平文萍,张琪,王晓玉..血管生成抑制剂联合化疗治疗复发性卵巢癌疗效与安全性Meta分析[J].中国实用妇科与产科杂志,2017,33(3):288-292,5.
